Inspire Medical Systems has delivered four consecutive quarters of exceptional earnings beats with an average surprise exceeding 180%, yet the forward earnings picture implies a severe contraction — the forward P/E of 31.5x is roughly 3.4 times the trailing multiple — while the stock trades in a confirmed technical downtrend, carries a debt-to-equity ratio of 3.7x, and faces 17% short interest; the reward-to-risk ratio of 1.49-to-1 falls short of standard entry criteria, making patience the appropriate posture.
Thesis pillars
- Cyclical Peak Valuation Risk↓Deteriorating
- Earnings Beat Streak Excellence→Stable
- High Short Interest Headwind↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 13, 2026· older than 90 days
Inspire Medical Systems, Inc. (INSP) Stock Analysis
Healthcare · Medical Devices
Sell if holding. At $61.90, A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Inspire system; Cyclical risk: PE expanding 2.2x (earnings normalizing).
Inspire Medical Systems develops and sells the Inspire system, an implantable hypoglossal nerve stimulator for moderate-to-severe obstructive sleep apnea patients who fail CPAP; the device received FDA PMA in 2014 and is approved in the EU, Japan, Singapore, and Thailand.... Read more
Sell if holding. At $61.90, A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Inspire system; Cyclical risk: PE expanding 2.2x (earnings normalizing). Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 6/9 gates (clean insider activity, news boost analyst 0.40, news boost analyst cluster(3), earnings proximity 98d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated Nov 3, 2026Recent Developments — Inspire Medical Systems, Inc.
Latest news
- NEWS Baird Maintains Neutral Rating on Inspire Medical Systems and Raises Price Target — fiscal.ai Nov 3, 2026 positive
- NEWS Inspire Medical Systems to Present at Stifel 2026 Healthcare Conference — fiscal.ai Nov 3, 2026
- NEWS Inspire Medical Systems (INSP) Prepares to Report Q3 Earnings Am - GuruFocus — GuruFocus Nov 1, 2026 neutral
- NEWS What To Expect From Inspire Medical Systems’s (INSP) Q2 Earnings - Yahoo Finance — Yahoo Finance Aug 2, 2026 neutral
- NEWS What To Expect From Inspire Medical Systems’s (INSP) Q2 Earnings - TradingView — TradingView Aug 2, 2026 neutral
Latest item Nov 3, 2026 · Generated 2026-11-04T12:04:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductInspire system10-K Item 1A: 'our dependency on our Inspire system for revenues'
Material Events(8-K, last 90d)
- 2026-05-05Item 5.02LOWStockholders approved amendment and restatement of 2018 Incentive Award Plan at April 30, 2026 Annual Meeting, authorizing 9,903,857 total shares (including 2,600,000 new shares), removing the evergreen feature, and adding minimum one-year vesting requirements.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Revenue shrinking — -7.6% YoY. Growth thesis broken unless recovery story develops.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $61.90, A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Inspire system; Cyclical risk: PE expanding 2.2x (earnings normalizing). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $58.39. Score 4.9/10, moderate confidence.
Analyst target: $62.49 (+1.0% upside). Prior stop was $58.39. Stop-loss: $58.39.
Concentration risk — Product: Inspire system; Cyclical risk: PE expanding 2.2x (earnings normalizing); Analyst target reached - limited upside remaining.
Inspire Medical Systems, Inc. trades at a P/E of 18.5 (forward 41.4). TrendMatrix value score: 4.4/10. Verdict: Sell.
24 analysts rate INSP, with a consensus score of 3.4/5. 16 analysts publish price targets averaging $69.
What does Inspire Medical Systems, Inc. do?Inspire Medical Systems develops and sells the Inspire system, an implantable hypoglossal nerve stimulator for...
Inspire Medical Systems develops and sells the Inspire system, an implantable hypoglossal nerve stimulator for moderate-to-severe obstructive sleep apnea patients who fail CPAP; the device received FDA PMA in 2014 and is approved in the EU, Japan, Singapore, and Thailand. Revenue is entirely from implant sales to hospitals and ambulatory surgery centers across 295 US and 21 international territories, with 125,000+ patients treated.